Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

The relation between the severity of breast cancer-related lymphedema and quality-of-life

Date

09 Oct 2016

Session

Poster display

Presenters

Mona Abou-Elenein

Citation

Annals of Oncology (2016) 27 (6): 497-521. 10.1093/annonc/mdw390

Authors

M.A. Abou-Elenein1, W.S. Makar1, H.M. Abdel-Azim1, S.A. Alsirafy2

Author affiliations

  • 1 Clinical Oncology Department, Kasr Al-ainy Center Of Clinical Oncology And Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, 11562 - Cairo/EG
  • 2 Palliative Medicine Unit, Kasr Al-ainy Center Of Clinical Oncology And Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo/EG
More

Resources

Abstract 2245

Background

Breast cancer-related lymphedema (BCRL) is a common problem that affects many breast cancer patients and may have a significant detrimental impact on their quality of life (QoL). The aim of the current study was to investigate the relation between the severity of BCRL and QoL of breast cancer patients.

Methods

The study included 102 breast cancer patients, of whom 64% had clinically evident arm lymphedema. BCRL was assessed by measuring the difference in circumference of upper limbs at four points (metacarpophalangeal joint, wrist and 10 cm above and below elbow). At each point the ratio of difference was calculated by dividing the difference in circumference by the circumference of the healthy arm. The sum of ratio differences was divided by 4 to get the average inter-limb circumference discrepancy (AICD). BCRL was defined as an AICD ≥5%. The severity of arm lymphedema was classified into grades 0 (no or 10- 30% AICD). QoL was assessed using the Functional Assessment of Cancer Therapy for Breast cancer patients with Lymphedema (FACT-B + 4).

Results

The average scores of the Functional Assessment of Cancer Therapy – General (FACT-G), Breast Cancer Subscale (BCS), Trial Outcome Index (TOI) and FACT-B + 4 differed significantly according to the presence of BCRL and its severity (table). The lowest QoL scores were observed among patient with grade 3 BCRL.

The relation between quality-of-life subscale/scale score and severity of breast cancer-related lymphedema

Quality of Life Scale Lymphedema grade p value
0 1 2 3
n = 41 n = 20 n = 32 n = 9
Mean (± standard deviation)
FACT-G 84 (17) 79 (16) 75 (11) 66 (23) 0.028
BCS 36 (8) 36 (8) 28 (9) 27 (14) 0.001
TOI 76 (15) 72 (12) 62 (19) 56 (25) 0.001
FACT-B + 4 120 (22) 114 (19) 103 (27) 94 (34) 0.004

Conclusions

The results of the current study illustrated a significant relationship between the severity of BCRL and QoL. This suggests that studies investigating the QoL of breast cancer patients should not only include BCRL as a dichotomous (absent/present) variable, but patients should be stratified according to the severity of BCRL as well.

Clinical trial identification

Legal entity responsible for the study

Kasr Al-Ainy School of Medicine, Cairo University

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings